BACKGROUND/AIMS: The aim of this study was to determine the decline in the estimated glomerular filtration rate (eGFR) in elderly persons and to compare estimates based on creatinine and cystatin C. METHODS: In the Cardiovascular Health Study, GFR changes in an elderly cohort were estimated from serum creatinine and cystatin C measured at baseline, year 3 and year 7 in 4,380 participants (age 72 +/- 5 years at entry). Outcomes were mean eGFR decline, incident chronic kidney disease (CKD) and rapid decline in eGFR (annual loss >3 ml/min/1.73 m(2)). RESULTS: Mean annual eGFR loss as estimated from creatinine was 0.4 +/- 3.6 ml/min/1.73 m(2), with 16% of the participants experiencing a rapid decline. Mean eGFR loss as estimated from cystatin C was 1.8 +/- 2.6, with 25% of the participants experiencing a rapid decline (p < 0.001 for both). Among participants without baseline CKD, incident CKD was detected at year 7 in 10% (n = 263) using creatinine and 19% (n = 544) using cystatin C (p < 0.001). Increasing age was the strongest predictor of rapid decline; adjusted odds ratios were 1.38 (1.16-1.65), 1.62 (1.31-1.99) and 2.96 (2.28-3.84) for participants aged 70-74, 75-79 and 80+ at baseline, compared with those aged 65-69. CONCLUSION: In elderly persons, cystatin C estimated substantially larger declines in kidney function than creatinine did. Defining the optimal measurement of kidney function in elderly persons should be a high priority for future research. Copyright 2009 S. Karger AG, Basel.
BACKGROUND/AIMS: The aim of this study was to determine the decline in the estimated glomerular filtration rate (eGFR) in elderly persons and to compare estimates based on creatinine and cystatin C. METHODS: In the Cardiovascular Health Study, GFR changes in an elderly cohort were estimated from serum creatinine and cystatin C measured at baseline, year 3 and year 7 in 4,380 participants (age 72 +/- 5 years at entry). Outcomes were mean eGFR decline, incident chronic kidney disease (CKD) and rapid decline in eGFR (annual loss >3 ml/min/1.73 m(2)). RESULTS: Mean annual eGFR loss as estimated from creatinine was 0.4 +/- 3.6 ml/min/1.73 m(2), with 16% of the participants experiencing a rapid decline. Mean eGFR loss as estimated from cystatin C was 1.8 +/- 2.6, with 25% of the participants experiencing a rapid decline (p < 0.001 for both). Among participants without baseline CKD, incident CKD was detected at year 7 in 10% (n = 263) using creatinine and 19% (n = 544) using cystatin C (p < 0.001). Increasing age was the strongest predictor of rapid decline; adjusted odds ratios were 1.38 (1.16-1.65), 1.62 (1.31-1.99) and 2.96 (2.28-3.84) for participants aged 70-74, 75-79 and 80+ at baseline, compared with those aged 65-69. CONCLUSION: In elderly persons, cystatin C estimated substantially larger declines in kidney function than creatinine did. Defining the optimal measurement of kidney function in elderly persons should be a high priority for future research. Copyright 2009 S. Karger AG, Basel.
Authors: L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman Journal: Ann Epidemiol Date: 1991-02 Impact factor: 3.797
Authors: L G Hunsicker; S Adler; A Caggiula; B K England; T Greene; J W Kusek; N L Rogers; P E Teschan Journal: Kidney Int Date: 1997-06 Impact factor: 10.612
Authors: Bruce A Perkins; Robert G Nelson; Betsy E P Ostrander; Kristina L Blouch; Andrzej S Krolewski; Bryan D Myers; James H Warram Journal: J Am Soc Nephrol Date: 2005-03-23 Impact factor: 10.121
Authors: Tomas Jernberg; Bertil Lindahl; Stefan James; Anders Larsson; Lars-Olof Hansson; Lars Wallentin Journal: Circulation Date: 2004-10-11 Impact factor: 29.690
Authors: Sandra V Giannelli; Christophe E Graf; François R Herrmann; Jean-Pierre Michel; Kushang V Patel; Francesco Pizzarelli; Luigi Ferrucci; Jack Guralnik Journal: Rejuvenation Res Date: 2011-09-28 Impact factor: 4.663
Authors: Ron T Gansevoort; Kunihiro Matsushita; Marije van der Velde; Brad C Astor; Mark Woodward; Andrew S Levey; Paul E de Jong; Josef Coresh Journal: Kidney Int Date: 2011-02-02 Impact factor: 10.612
Authors: Nisha Bansal; Eric Vittinghoff; Carmen A Peralta; Michael G Shlipak; Vanessa Grubbs; David R Jacobs; David Siscovick; Michael Steffes; John Jeffrey Carr; Kirsten Bibbins-Domingo Journal: Am J Epidemiol Date: 2013-06-27 Impact factor: 4.897
Authors: Dena E Rifkin; Ronit Katz; Michel Chonchol; Michael G Shlipak; Mark J Sarnak; Linda F Fried; Anne B Newman; David S Siscovick; Carmen A Peralta Journal: Am J Hypertens Date: 2013-05-24 Impact factor: 2.689
Authors: Erica Chan Day; Yongmei Li; Ana Diez-Roux; Namratha Kandula; Andrew Moran; Sylvia Rosas; Michael G Shlipak; Carmen A Peralta Journal: Nephrol Dial Transplant Date: 2010-11-04 Impact factor: 5.992
Authors: Carmen A Peralta; Ronit Katz; Michael Shlipak; Ruth Dubin; Ian DeBoer; Nancy Jenny; Annette Fitzpatrick; Carol Koro; Bryan Kestenbaum; Joachim Ix; Mark Sarnak; Mary Cushman Journal: Am J Nephrol Date: 2011-11-01 Impact factor: 3.754
Authors: Cassianne Robinson-Cohen; Ronit Katz; Dariush Mozaffarian; Lorien S Dalrymple; Ian de Boer; Mark Sarnak; Mike Shlipak; David Siscovick; Bryan Kestenbaum Journal: Arch Intern Med Date: 2009-12-14
Authors: Chris T Longenecker; Rebecca Scherzer; Peter Bacchetti; Cora E Lewis; Carl Grunfeld; Michael G Shlipak Journal: AIDS Date: 2009-06-01 Impact factor: 4.177